A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Golimumab (Primary) ; Antipsoriatics; Antirheumatics; Tumour necrosis factor receptor antagonists
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Janssen Biotech
- 24 Nov 2017 Planned number of patients changed from 1000 to 400.
- 24 Nov 2017 Planned End Date changed from 5 Sep 2017 to 1 Jun 2018.
- 24 Nov 2017 Planned primary completion date changed from 5 Sep 2017 to 1 Jun 2018.